TREATMENT OF CHRONIC STABLE ASTHMA WITH DRUGS ACTIVE ON THE 5-LIPOXYGENASE PATHWAY
TREATMENT OF CHRONIC STABLE ASTHMA WITH DRUGS ACTIVE ON THE 5-LIPOXYGENASE PATHWAY
复制标题
DOI：
10.1159/000237013
复制
发表时间：
1995-05-01
影响因子：
2.8
通讯作者：
ISRAEL, E
中科院分区：
文献类型：
--
作者：
DRAZEN, JM;ISRAEL, E
现在已经确定，在哮喘反应期间，5-脂氧合酶产物在气道中被合成和释放。通过研究5-脂氧合酶抑制剂和白三烯Dq受体拮抗剂在慢性稳定型哮喘患者中的作用，这些产品在哮喘反应中的重要性已经确立。在这项研究中，我们回顾了证明慢性给药zileuton（一种5-脂氧合酶抑制剂）与轻度至中度哮喘患者气道功能改善、哮喘症状减轻和哮喘药物使用需求减少相关的数据。
It is now established that 5-lipoxygenase products are synthesized and released in the airway during asthmatic reactions. The importance of these products in the asthmatic response has been established through study of the effects of 5-lipoxygenase inhibitors and leukotriene Dq receptor antagonists in patients with chronic stable asthma. In this study we review the data demonstrating that chronic administration of zileuton, an inhibitor of 5-lipoxygenase, is associated with improved airway function, decreased asthma symptoms and decreased need for asthma medication use in patients with mild to moderate asthma.